Molecular docking analysis of the protein-protein interaction between RelA-associated inhibitor and tumor suppressor protein p53 and its inhibitory effect on p53 action

Cancer Science

Volumn 99, Issue 3, 2008, Pages 615-622

  Tomoda, Keisuke ^a   Takahashi, Naoko ^a   Hibi, Yurina ^a   Asamitsu, Kaori ^a   Ishida, Hirokazu ^b   Kondo, Toshiharu ^b   Fujii, Yoshitaka ^a   Okamoto, Takashi ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b ESI GROUP   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; I KAPPA B; MUTANT PROTEIN; PROTEIN BAX; PROTEIN P53; RELA ASSOCIATED INHIBITOR PROTEIN; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; DRUG RESEARCH; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; MOLECULAR DOCKING; MOLECULAR MODEL; PREDICTION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; SITE DIRECTED MUTAGENESIS; VALIDATION STUDY;

EID: 38949105821     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2007.00723.x     Document Type: Article

References (28)

1. Yang JP, Hori M, Sanda T, Okamoto T. Identification of a novel inhibitor of nuclear factor-κB, Rel-A-associated inhibitor. J Biol Chem 1999; 274: 15.662-70.
2. Takahashi N, Kobayashi S, Jiang X et al. Expression of 53BP2 and ASPP2 proteins from TP53BP2 gene by alternative splicing. Biochem Biophys Res Commun 2004; 315: 434-8.
3. Yang JP, Hori M, Takahashi N, Kawabe T, Kato H, Okamoto T. NF-κB subunit p65 binds 53BP2 and inhibits cell death induced by 53BP2. Oncogene 1999; 18: 5177-86.
4. Takada N, Sanda T, Okamoto H et al. RelA-associated inhibitor blocks transcription of human immunodeficiency virus type 1 by inhibiting NF-κB and Sp1 actions. J Virol 2002; 76: 8019-30.
5. Bergamaschi D, Samuels Y, O'Neil N et al. iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human. Nat Genet 2003; 33: 162-7.
6. Samuels Y, O'Connor DJ, Bergamaschi D et al. ASPP proteins specifically stimulate the apoptotic function of p53. Mol Cell 2001; 8: 781-94.
7. Okamoto T, Sanda T, Asamitsu K. NF-κB signaling and carcinogenesis. Curr Pharm Des 2007; 13: 447-62.
8. Zang X, Wang M, Zhou C, Chen S, Wang J. The expression of iASPP in acute leukemias. Leuk Res 2005; 29: 179-83.
9. Herron BJ, Rao C, Liu S et al. A mutation in NF-κB interacting protein 1 results in cardiomyopathy and abnormal skin development in wa3 mice. Hum Mol Genet 2005; 14: 667-77.
10. Zang X, Diao S, Rao Q et al. Identification of a novel isoform of iASPP and its interaction with p53. J Mol Biol 2007; 368: 1162-71.
11. Baker SJ, Markowitz S, Fearon ER, Willson JV, Vogelstein B. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 1990; 249: 912-15.
12. Sato T, Asamitsu K, Yang JP et al. Inhibition of human immunodeficiency virus type 1 replication by a bioavailable serine/threonine kinase inhibitor, fasudil hydrochloride. AIDS Res Hum Retroviruses 1998; 14: 293-8.
13. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995; 80: 293-9.
14. Nakano K, Mizuno T, Sowa Y et al. Butyrate activates the WAF1/Cip1 gene promoter through Sp1 site in a p53-negative human colon cancer cell line. J Biol Chem 1997; 272: 22.199-206.
15. Asamitsu K, Tetsuka T, Kanazawa S, Okamoto T. RING finger protein AO7 supports NF-κB-mediated transcription by interacting with the transactivation domain of the p65 subunit. J Biol Chem 2003; 278: 26.879-87.
16. 2 checkpoint abrogation. Cancer Res 1999; 59: 5887-91.
17. Tetsuka T, Uranishi H, Imai H et al. Inhibition of nuclear factor-κB-mediated transcription by association with the amino-terminal enhancer of split, a Groucho-related protein lacking WD40 repeats. J Biol Chem 2000; 275: 4383-90.
18. Uranishi H, Tetsuka T, Yamashita M et al. Involvement of the prooncoprotein TLS (translocated in liposarcoma) in nuclear factor-κB p65-mediated transcription as a coactivator. J Biol Chem 2001; 276: 13.395-401.
19. Kondo T, Ishida H, Yamauchi R, Watanabe E, Hirose C, Go M. GreenPepper: The docking prediction software of protein complex. In: The 15th International Conference on Genome Informatics, Posters and Software Demonstrations, p. 128, 2004. Available from URL: http://www.jsbi.org/ molecules/journal/index.php/GIW04/GIW04Poster.html
20. Palm PN, Krippahl L, Wampler JE, Moura JJG. BIGGER: A new (soft) docking algorithm for predicting protein interactions. Proteins 2000; 39: 372-84.
21. Glaser F, Steinberg DM, Vakser IA, Ben-Tal N. Residue frequencies and pairing preferences at protein-protein interfaces. Proteins 2001; 43: 89-102.
22. Gorina S, Pavletich NP. Structure of the p53 tumor suppressor bound to the Ankyrin and SH3 domains of 53BP2. Science 1996; 274: 1001-5.
23. 2/M. Mol Cell Biol 1996; 16: 3884-92.
24. Slee EA, Gillotin S, Bergamaschi D et al. The N-terminus of a novel isoform of human iASPP is required for its cytoplasmic localization. Oncogene 2004; 23: 9007-16.
25. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993; 74: 609-19.
26. Harper JW, Adams GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993; 75: 805-16.
27. Soussi T, Lozano G. p53 mutation heterogeneity in cancer. Biochem Biophys Res Commun 2005; 331: 834-42.
28. Soussi T. p53 alterations in human cancer: More questions than answers. Oncogene 2007; 26: 2145-56.